Vivera Pharmaceuticals, in partnership with Burkhan Group, is excited to announce a new testing initiative in Southern California.
| NEWPORT BEACH, Calif., Jan. 25, 2021 /PRNewswire/ -- Vivera Pharmaceuticals, in partnership with Burkhan Group, is excited to announce a new testing initiative in Southern California. Together, the two are paving the way for easier access to rapid testing as area businesses develop back to work protocols.
The two companies are working together to expand outreach to Southern California’s economic power players. With Vivera’s suite of lower cost COVID-19 testing, including antigen and RT-PCR diagnostic testing, centralized site-specific protocols are easier to build than ever. With more tests efficiently processed by CLIA-certified laboratory testing partners, businesses can begin to plan staged reopening procedures. “Even with the introduction of the vaccine, it is important to keep expanding access to testing. By providing easy access to RT-PCR with lab and home-based collection, and lab site rapid tests, Vivera is working with the businesses and laboratories who rely on us to ensure supply,” stated Paul Edalat, Vivera Pharmaceuticals’ CEO. Burkhan’s focus is to invest with companies that can bring revolutionary technologies and experiences to our society to help better our standards of living for today. “As an organization that deals with the day to day challenges presented by the pandemic, Burkhan is very proud to be a part of this initiative,” said Shahal Khan Burkhan’s Founder, “Providing the latest in accessible COVID-19 testing is a way to increase efficiency and get our local economies back to work.” The two companies are working together to expand outreach to Southern California’s economic power players, including the film and television industry, hospitality, and travel sectors. About Vivera Pharmaceuticals, Inc. About Burkhan Contact: Vivera Pharmaceuticals
SOURCE Vivera Pharmaceuticals, Inc. |
View original content to download multimedia:
